在心力衰竭中SGLT2抑制与保存的喷射分数 - 新的前沿
Inês Aguiar-Neves1, Diogo Santos-Ferreira1,2, Ricardo Fontes-Carvalho1,2
1Cardiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, 4434-502 Vila Nova de Gaia, Portugal.
Reviews in cardiovascular medicine
|July 30, 2024
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂在用保存喷射分数 (HFpEF) 治疗心力衰竭方面表现有前途. 临床试验表明,在使用SGLT2抑制剂的HFpEF患者中,心血管结果得到改善,住院时间减少.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一个重大的临床挑战,治疗选择有限.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂在2型糖尿病和心力衰竭中具有降低射出分数 (HFrEF) 的益处.
研究的目的:
- 分析HFpEF中SGLT2抑制剂的当前临床证据.
- 探索HFpEF中SGLT2抑制的潜在心脏保护机制.
- 讨论SGLT2抑制剂在HFpEF管理中的未来作用.
主要方法:
- 随机对照试验和元分析的综述.
- 对心血管和结局数据的分析.
- 探索拟议的行动机制.
主要成果:
- 主要的临床试验表明SGLT2抑制剂 (empagliflozin,dapagliflozin) 改善了HFpEF中的心血管结果.
- 使用SGLT2抑制剂观察到心力衰竭住院病例的显著减少.
- 无论糖尿病状况如何,在不同患者亚组中,好处似乎是一致的.
结论:
- SGLT2 抑制剂代表了对HFpEF的一个有前途的治疗类.
- 进一步的研究正在进行中,以阐明精确的心脏保护机制.
- 抑制SGLT2有可能在HFpEF管理中得到广泛应用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


